altinicline

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 437196684

| IUPAC_name = (2S)-3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine

| image = Altinicline.svg

| width = 175

| tradename =

| routes_of_administration =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 179120-92-4

| ATC_prefix = None

| ATC_suffix =

| PubChem = 3036156

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 2300234

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = RJ9V9V09VM

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 111659

| C=12 | H=14 | N=2

| smiles = c2ncc(C#C)cc2C1CCCN1C

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3/t12-/m0/s1

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = NUPUDYKEEJNZRG-LBPRGKRZSA-N

}}

Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype.{{cite journal | vauthors = Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, Suto C, Washburn M, Lloyd GK, McDonald IA | display-authors = 6 | title = Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist | journal = Pharmaceutica Acta Helvetiae | volume = 74 | issue = 2–3 | pages = 125–30 | date = March 2000 | pmid = 10812948 | doi = 10.1016/S0031-6865(99)00024-2 }}{{cite journal | vauthors = Wagner FF, Comins DL | title = Expedient five-step synthesis of SIB-1508Y from natural nicotine | journal = The Journal of Organic Chemistry | volume = 71 | issue = 22 | pages = 8673–5 | date = October 2006 | pmid = 17064057 | doi = 10.1021/jo0616052 }} It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models,{{cite journal | vauthors = Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND | title = Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist | journal = Brain Research | volume = 1234 | pages = 16–24 | date = October 2008 | pmid = 18692487 | doi = 10.1016/j.brainres.2008.07.063 | s2cid = 23547813 }} and progressed as far as Phase II clinical trials for Parkinson's disease,{{cite journal | author = The Parkinson Study Group | title = Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease | journal = Neurology | volume = 66 | issue = 3 | pages = 408–10 | date = February 2006 | pmid = 16476941 | doi = 10.1212/01.wnl.0000196466.99381.5c | s2cid = 31720763 }} where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.